Learn how you can help protect your patients this RSV season
To continue offering insights and information throughout the RSV season, we're pleased to share the 2024 Expert Series webinar recordings. This series features key opinion leaders from the RSV community with diverse backgrounds and experiences, including pediatrics, infectious disease, obstetrics, and neonatology, in both clinic and hospital settings.
Available any time, these webinars give you the opportunity to learn from leading experts about integrating Beyfortus into your practice, on your schedule.
Beyfortus is the first and only long-acting antibody indicated for the prevention of RSV lower respiratory tract disease in¹:
- Neonates and infants born during or entering their first RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
Monoclonal Antibody for the Prevention of RSV-LRTI in Infants
BROADCAST JULY 31, 2024
Dr Christopher Belcher, a pediatric infectious disease specialist, and Dr Keisha Callins, an obstetrician/gynecologist, copresent a discussion on Beyfortus, a monoclonal antibody for the prevention of RSV disease in infants. Their presentation includes the RSV disease burden, the Beyfortus mechanism of action and clinical recommendations, clinical and real-world data, and implementation recommendations to help ensure optimal uptake and minimize health disparities.
Christopher Belcher, MD, FAAP
Pediatric Infectious Disease Specialist
Ascension Medical Group at St. Vincent Infectious Disease, Indiana
Keisha Callins, MD, MPH
Obstetrician/Gynecologist
Community Health Care Systems, Georgia
lmplementing Beyfortus lnto Clinical Practice
BROADCAST SEPTEMBER 10, 2024
Dr Zubin Shah, a neonatologist, and Dr Suzanne Staebler, a neonatal nurse practitioner, present an interactive discussion on implementing Beyfortus into clinical practice. Their presentation addresses reasons to prevent RSV as well as the performance of Beyfortus in both clinical trials and real-world settings. Drs Shah and Staebler conclude with discussing Beyfortus implementation considerations in the hospital setting for the 2024-2025 season.
Zubin Shah, MD, FAAP
Neonatologist
Baylor University Medical Center at Pediatrix Medical Group, Texas
Suzanne Staebler, DNP, APRN, NNP-BC, FAANP, FAAN
Neonatal Nurse Practitioner
Trinity Mother Frances Hospital, and Policy Advisor, National Coalition for Infant Health, Texas
.
RSV-LRTI, respiratory syncytial virus lower respiratory tract infection
Important Safety Information
Reference: 1. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi.
